Latest Regulatory News

Coolabah Metals Limited is set to transform into a producing miner with its $15-20 million capital raise, conditional on acquiring Broken Hill Mines Pty Ltd and resuming ASX trading.

InFocus Group Holdings has secured a $3.25 million contract to develop a cutting-edge white-label iGaming platform for Taiwanese firm TG Solutions, marking a significant expansion into the digital gaming sector.

M3 Mining Limited has abandoned its energy sector acquisition plans, selling its M3 Energy subsidiary to Jerboa Energy Ltd and recommitting to its core mineral exploration projects.

Antilles Gold’s joint venture has inked key offtake agreements for all gold and copper/gold concentrates from the Nueva Sabana mine, boosting project financing prospects.

PainChek Limited has secured a pivotal reseller and integration deal with Eldermark Software, positioning its AI-driven pain assessment app for a major US market rollout pending FDA approval.

Carnaby Resources has reported promising first drill results from its Trekelano Project in Mt Isa, confirming broad, high-grade copper-gold mineralisation that could significantly enhance the Greater Duchess Copper Gold Project.

Optiscan Imaging Ltd has reached a pivotal milestone with the completion of its cloud-based telepathology software MVP, enabling secure, real-time remote collaboration for digital pathology.

Silver Mines Limited has received a key determination from the NSW Planning Secretary confirming the transmission line as part of the Bowdens Silver Project development, paving the way for progress towards final consent.

Sunshine Metals has secured a binding agreement to acquire the high-grade Sybil Epithermal Gold Project near Charters Towers, Queensland, aiming to fast-track near-surface gold production. The acquisition, valued at A$1.225 million, aligns with Sunshine’s strategy to expand its district presence and leverage underexplored epithermal systems.

ALS Limited has announced a fully underwritten A$350 million equity placement to fund major upgrades to its global laboratory network and support future growth initiatives, aiming for mid single-digit EPS accretion by FY25 pro forma.

ALS Limited delivered a robust FY25 performance with 16% revenue growth to $3 billion and underlying EBIT rising 4.7% to $515 million, driven by strong organic growth and strategic acquisitions. The company is advancing its Nuvisan integration ahead of schedule and has unveiled a $230 million investment plan to expand key laboratories, positioning itself for sustained growth amid market uncertainties.

ALS Limited reported a robust FY25 with $3 billion revenue driven by Life Sciences growth and resilient Commodities, announcing a $350 million equity raise to fund strategic expansion.